These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15501347)

  • 21. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to hydroxychloroquine due to smoking in a patient with lupus erythematosus tumidus.
    Hügel R; Schwarz T; Gläser R
    Br J Dermatol; 2007 Nov; 157(5):1081-3. PubMed ID: 17854374
    [No Abstract]   [Full Text] [Related]  

  • 25. Antimalarial agents and lupus.
    Wallace DJ
    Rheum Dis Clin North Am; 1994 Feb; 20(1):243-63. PubMed ID: 8153401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
    Spinelli FR; Moscarelli E; Ceccarelli F; Miranda F; Perricone C; Truglia S; Garufi C; Massaro L; Morello F; Alessandri C; Valesini G; Conti F
    Lupus; 2018 Sep; 27(10):1616-1623. PubMed ID: 29954281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 28. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y; Arai S; Eto H; Kishimoto M; Okada M
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.
    Kuhn A; Sigges J; Biazar C; Ruland V; Patsinakidis N; Landmann A; Amler S; Bonsmann G;
    Br J Dermatol; 2014 Sep; 171(3):571-9. PubMed ID: 24673427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antimalarials in lupus erythematosus treatment].
    Woźniacka A
    Przegl Lek; 2002; 59(3):179-82. PubMed ID: 12184034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
    Pelle MT; Callen JP
    Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosacea-like cutaneous lupus erythematosus: an atypical presentation responding to antimalarials.
    Marzano AV; Lazzari R; Polloni I; Boneschi V; Crosti C
    Acta Derm Venereol; 2013 Jan; 93(1):106-7. PubMed ID: 23053047
    [No Abstract]   [Full Text] [Related]  

  • 34. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
    Parke A; West B
    J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.
    Pakchotanon R; Gladman DD; Su J; Urowitz MB
    J Rheumatol; 2018 Jan; 45(1):90-94. PubMed ID: 29142038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
    Pawlak-Buś K; Gaca-Wysocka M; Grzybowski A; Leszczyński P
    Pol Merkur Lekarski; 2016 Mar; 40(237):202-6. PubMed ID: 27088206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus.
    Rahman P; Gladman DD; Urowitz MB
    J Rheumatol; 1998 Sep; 25(9):1716-9. PubMed ID: 9733451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
    Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
    Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
    Zeidi M; Kim HJ; Werth VP
    J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effect of hydroxychloroquine on cutaneous lupus erythematosus in a Japanese girl.
    Yamamoto T; Hiraiwa T
    J Dermatol; 2014 Apr; 41(4):357-9. PubMed ID: 24617496
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.